grant
Biodegradable polymeric microparticles comprised of acetalated dextran induce immune tolerance
Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 15 Nov 2024Deadline 31 Oct 2029
NIHUS FederalResearch GrantFY2026Adoptive TransferAffectAgreementAmericanAnimal ModelAnimal Models and Related StudiesAntibodiesAntigen PresentationAntigen TargetingAntigensAutoantigensAutoimmuneAutoimmune DiseasesAutologous AntigensB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBindingBiocompatible MaterialsBiodistributionBiomaterialsBiopolymersBlood NeutrophilBlood Polymorphonuclear NeutrophilBlood SerumBp35C2B8 Monoclonal AntibodyCD20CD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCSIFCSIF-10Cell BodyCell surfaceCellsClinicClinicalClinical TreatmentComplementComplement ProteinsComplexCouplingCytokine Synthesis Inhibitory FactorDataDendritic CellsDextransDiameterDiseaseDisorderDisseminated SclerosisDoseDrynessEAEEmulsionsEncapsulatedEngineeringExperimental Allergic EncephalitisExperimental Allergic EncephalomyelitisExperimental Autoimmune EncephalitisExperimental Autoimmune EncephalomyelitisFrequenciesGenerationsGlycolatesGoalsGrantIL-10IL10IL10AImmuneImmune ToleranceImmune mediated therapyImmune responseImmune systemImmunesImmunologic ToleranceImmunologically Directed TherapyImmunologistImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIn VitroIn vivo analysisIncubatedInjectionsInterleukin 10 PrecursorInterleukin-10KO miceKnock-out MiceKnockout MiceLeu-16MOG glycoproteinMS treatmentMS4A1MS4A1 geneMS4A2MabTheraMacrophageMarrow NeutrophilMediatingMethodsMiceMice MammalsModelingMolecular InteractionMultiple SclerosisMurineMusMφNeutrophilic GranulocyteNeutrophilic LeukocyteNull MousePeptidesPhagocytesPhagocytic CellPharmaceuticsPharmacy (field)PhenotypePolymersPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPopulationProductionProteinsProteomicsPublishingRNA SeqRNA sequencingRNAseqRegulatory T-LymphocyteRituxanRouteSafetySelf ToleranceSelf-AntigensSerumSiteSurfaceSymptomsSystemT-CellsT-LymphocyteT4 CellsT4 LymphocytesTechniquesTechnologyToxic effectToxicitiesTregVaccinesVeiled CellsWorkadoptive B cell therapyadoptive B cell transferamebocyteautoimmune attackautoimmune conditionautoimmune destructionautoimmune disorderautoimmune encephalomyelitisautoimmune pathogenesisautoimmunity diseasebiodegradable polymerbiological materialbioresorbable polymercentral nervous system demyelinating diseasecentral nervous system demyelinating disorderclinical interventionclinical therapycomplementationcytokinedegradable polymerdesigndesigningdextrandriving forceglycolic acidhost responseimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune system toleranceimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune unresponsivenessimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunological paralysisimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedin vivoin vivo evaluationin vivo testinginsular sclerosismodel of animalmultiple sclerosis therapymultiple sclerosis treatmentmyelin oligodendrocyte glycoproteinneutrophilnoveloligodendrocyte-myelin glycoproteinparticleparticle therapypharmaceuticpolymerpolymericregulatory T-cellsrituximabside effectsubcutaneoussubdermalsuccesstherapy optimizationthymus derived lymphocytetranscriptome sequencingtranscriptomic sequencingtreatment optimizationtrial regimentrial treatment
Description preview
ABSTRACT
The clinical treatment of autoimmune diseases traditionally uses immunosuppression to curtail the pathogenesis
of the autoimmune disease. An alternative for general immune suppression, is antigen specific tolerance.
However, there is currently no antigen specific tolerance therapy in the clinics. We have recently discovered…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click